StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) stock

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.18+0.24 (+25.51%)

Close on Nov 17, 2026Market cap $51.50MP/E –Yield –

Gain Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Gain Therapeutics's profit margin for the twelve months ending Dec 31, 2023 was -40354.3%. For fiscal 2023 it was -40354.3%, against -12555.1% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 2023-40354.3%−27799.2
FY2022Dec 31, 2022-12555.1%−4136.3
FY2021Dec 31, 2021-8418.9%+3968.8
FY2020Dec 31, 2020-12387.7%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2023Mar 31, 2023-9310.1%+7744.3
Q2 FY2022Jun 30, 2022-5347.3%−1358.8
Q1 FY2022Mar 31, 2022-7271.6%+39235.3
Q4 FY2021Dec 31, 2021-7452.2%+10664.5
Q3 FY2021Sep 30, 2021-17054.4%−5191.1
Q2 FY2021Jun 30, 2021-3988.5%+4537.5
Q1 FY2021Mar 31, 2021-46506.9%−37751.2
Q4 FY2020Dec 31, 2020-18116.7%–
Q3 FY2020Sep 30, 2020-11863.4%–
Q2 FY2020Jun 30, 2020-8526.0%–
Q1 FY2020Mar 31, 2020-8755.7%–

More Gain Therapeutics figures

See a number that looks wrong?